INKT - MiNK Therapeutics, Inc.

11.34
-0.400   -3.527%

Share volume: 33,442
Last Updated: 04-22-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$11.74
-0.40
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 43%
Liquidity 31%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.54%
1 Month
28.57%
3 Months
-9.28%
6 Months
-19.92%
1 Year
49.01%
2 Year
1,201.95%
Key data
Stock price
$11.34
P/E Ratio 
0.00
DAY RANGE
$11.33 - $11.96
EPS 
-$2.10
52 WEEK RANGE
$6.34 - $76.00
52 WEEK CHANGE
$51.20
MARKET CAP 
63.321 M
YIELD 
N/A
SHARES OUTSTANDING 
4.694 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-28-2025
NEXT EARNINGS DATE
05-13-2025
BETA 
1.37
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$81,306
AVERAGE 30 VOLUME 
$71,486
Company detail
CEO: Jennifer S. Buell
Region: US
Website: minktherapeutics.com
Employees: 30
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.

Recent news